Research
Hormonal
GLP-1 analogs are widely used in Saudi Arabia for diabetes management and show some weight loss efficacy, but there is no trial data for their use in obesity-only patients in the country.
GLP-1 analogs are used in Saudi Arabia for diabetes, but there is no specific trial data for obesity-only patients. Use with caution and monitor weight loss.
LimitedRefutesLOW confidence
There is no trial data for the use of GLP-1 analogs in SA, despite their widespread use.
Why this rating
Based on real-world usage data, not RCTs for obesity.
Source
Prevalence, risk factors, and interventions for obesity in Saudi Arabia: A systematic review
Victoria Salem et al. · Obesity Reviews · 2022
DOI 10.1111/obr.13448
systematic_reviewCited 138×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- High levels of physical inactivity and consumption of sugary beverages are primary drivers of obesity prevalence in Saudi Arabia, with inactive individuals showing significantly lower risk reduction compared to active males.Good
- Intensive lifestyle interventions in Saudi Arabia achieve an average weight loss of 4.1%, which is favorable compared to other published interventions but fails to meet the >5% threshold for significant comorbidity risk reduction.Moderate
- Bariatric surgery in Saudi Arabia achieves an average weight loss of 18% (33.6 kg) at 6 months, with high rates of sleeve gastrectomy and a young patient demographic.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →